Academic Editor:
Department
of Pharmacy Practice, College of Pharmacy, Sri Ramakrishna Institute of
Paramedical Sciences, Coimbatore, Tamil Nadu, India
Correspondence: Dr. Prajith V, Department of
Pharmacy Practice, College of Pharmacy, Sri Ramakrishna Institute of
Paramedical Sciences, Coimbatore, Tamil Nadu, India, Email: prajithpharmd@gmail.com
Citation: Dr. Prajith V (2021) Renal Safety of Bisphosphonates – A Systematic
Review.
Int J Med Clin Case Rep, 1(1);1-6.
Copyright: © 2021, Dr. Prajith V. This is an open-access article distributed
under the terms of the Creative Commons Attribution 4.0 International License,
which permits unrestricted use, distribution and reproduction in any medium,
provided the original author and source are credited
Abstract
Background: Thoughbisphosphonates
are the gold standard for the treatment of different metabolic bone disorders
including osteoporosis for more than five decades, its safety and tolerability
in patients with compromised kidney function is not well known. With
age-related bone disorders and renal insufficiency becoming more prevalent worldwide,
it is essential to understand the effect of bisphosphonates on patients with
compromised renal function. This review aims to analyze the clinical data
available on safety of bisphosphonates on patients with different levels of renal
function.
Methodology: A broad search
of PubMed and the Cochrane Central Register of Controlled Trials was conducted
to select randomized controlled trials and clinical trials that evaluated the
safety and tolerability of bisphosphonate in patients with different levels of renal
function between 2000 and 2018.
Results: Out of 30388
titles and abstract reviewed, 16 articles were included in the final analysis. Except
for risedronate causing a significant increase in eGFR at months 3 and 12 and zoledronic
acid increasing serum creatinine by 2.77% from baseline, all bisphosphonates
are relatively safe and well tolerated by the kidneys.
Conclusion: The evidence
from this review suggests that the bisphosphonates are generally well tolerated
with ten trials registering no drug-related withdrawals and other studies showing
only very nominal withdrawals due to adverse effects.
Keywords: Bisphosphonates, Randomized Controlled Trials, Renal
Function, Osteoporosis, Renal Insufficiency
.png)
.jpg)
.gif)
.jpg)
